Intravacc, a leader in translational research and the development of vaccines against infectious diseases and therapeutic vaccines, has launched its new hybrid business model that aims to lead to further innovation and sustainable growth over the next five years.   On the one hand, Intravacc’s new business model leans on contract research and small-scale GMP production for clinical research on vaccine efficacy and safety (CDMO), and on the other hand, it focuses on the independent development an...